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Combination Antihypertensive Therapy: 
Does It Have a Role in Rational Therapy? 
Bernard Waeber and Hans R. Brunner 
The pharmacological treatment of hypertension 
allows one to reduce substantially the risk of 
developing a cardiovascular complication. It 
appears more and more important to bring blood 
pressure to normal values in order to get the 
maximal benefit from antihypertensive therapy. 
Blood pressure lowering drugs make it possible to 
control blood pressure in about half of the patients 
when administered as monotherapy. The fraction 
of patients with a normal blood pressure can be 
markedly increased by combining drugs acting by 
different mechanisms. Low doses of 
antihypertensive agents are generally enough when 
coadministered. This helps to keep the incidence 
of side effects minimal and facilitates the patient’s 
compliance with long-term treatment. Low-dose, 
fixed-dose combination therapy may therefore 
represent a valuable option not only to treat 
hypertensive patients unresponsive to drugs given 
as monotherapy, but also to initiate the 
treatment. Am J Hypertens 1997;10:1318-1378 
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E ssential hypertension is a common and highly heterogenous disease.‘,’ A complex interplay exists among genetic and environ- mental factors so that predisposed persons 
tend to become hypertensive under certain conditions. 
The pathogenetic mechanisms involved in the abnor- 
mal blood pressure elevation are multiple and may 
differ considerably from patient to patient. Not sur- 
prisingly, therefore, not every patient responds to ev- 
ery antihypertensive drug in the same fashion. Some 
patients normalize their blood pressure when given a 
compound acting by a given specific mechanism 
whereas others do not. This means that the treatment 
has to be individualized for each patient. 
Five major classes of antihypertensive agents are 
now available to treat hypertensive patients: diuretics, 
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P-blockers, angiotensin converting enzyme (ACE) in- 
hibitors, calcium antagonists, and a,-adrenoceptor 
blockers3 These drugs with different modes of action 
can be used as first-line therapy and, when required, 
might be combined. Most likely angiotensin II recep- 
tor antagonists will also be recommended soon as an 
acceptable option to initiate antihypertensive therapy. 
Despite the availability of an increasing number of 
antihypertensive drugs, the management of hyperten- 
sion in everyday practice remains a difficult task. This 
is reflected by the results of a recent analysis per- 
formed in 10,222 hypertensive patients, which has 
shown a high rate of discontinuation of antihyperten- 
sive drugs in general practice.* Only 40% to 50% of 
patients having had a new course of treatment initi- 
ated with a diuretic, a p-blocker, an ACE inhibitor, or 
a calcium antagonist were still on the same drug 6 
months later. Whether the treatments were terminated 
because of insufficient efficacy or poor tolerability 
could not be decided from this investigation, which 
was based on the analysis of prescriptions. Conceiv- 
ably, this high rate of treatment changes might have 
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FIGURE 1. Response rate to 
long-term treatment with dilfiazem 
(DILT), atenolol (ATEN), clonidine 
(CLON), kydrocklorofkiazide (HCTZ), 
captop-il (CAPT), prawsine (PRAZ), 
and placebo (PLAC). The open col- 
umns correspond to the results ob- 
tained at the end of the titration pe- 
riod and show the percentage of pa- 
tients with a diastolic blood pressure 
<90 mm Hg. The hatched columns 
depict the data observed at the end of 
the 1 year treatment. Responders 
were defined at that time as patients 
with a diastolic blood pressure <90 
mm Hg at the end of the titration 
period and <95 mm Hg at the end of 
the 1 year follow-up. The numbers at 
the bottom of the bars indicate the 
number of patients included in rack 
group (adapted from Materson BJ 
et aP1. 
DILT CLON ATEN HCTZ PRAZ CAPT PLAC 
0 DBP < 90 mmHg at the end of the titration phase 
m DBP < 90 mmHg at the end of the titration phase 
+ < 95 mmHg at the end of one year treatment 
had an adverse impact on the patients’ compliance 
and, consequently, on the long-term quality of blood 
pressure control. 
The question now arises of how the available anti- 
hypertensive drugs should be used to get the greatest 
benefit, ie, to achieve optimal blood pressure control 
without altering the patient’s quality of life, the ulti- 
mate goal of lifelong treatment being to prevent as 
much as possible the occurrence of cardiovascular 
complications. Different approaches can be advocated 
to initiate treatment. One is to try to find for each 
patient a drug that is at the same time effective and 
well tolerated when administered as monotherapy (se- 
quential monotherapy). Another is to associate a priori 
low doses of drugs lowering blood pressure by differ- 
ent mechanisms (combined therapy). Both ways of 
treating hypertension have advantages and limita- 
tions. The present paper is aimed at reviewing a few 
clinical trials illustrating the rationale for single and 
combined antihypertensive therapy. 
TAILORED THERAPY USING 
MONOSUBSTANCES 
In general, any antihypertensive drug might be ex- 
pected to control blood pressure in about 40% to 50% 
of hypertensive patients. This is illustrated by the 
results of a large trial having compared recently the 
five standard, first-choice treatments recommended 
nowadays, as well as a centrally acting antihyperten- 
sive agent (clonidine).5 In this study 1,292 hyperten- 
sive men (diastolic blood pressure of 95 to 109 mm 
Hg) were randomized to receive for 1 year either 
placebo or the diuretic hydrochlorothiazide (12.5 to 50 
mg per day), the P-blocker atenolol (25 to 100 mg/ 
day), the ACE inhibitor captopril(25 to 100 mg/day), 
a sustained-release preparation of the calcium antag- 
onist diltiazem (120 to 360 mg/day), the cY,-blocker 
prazosin (4 to 20 mg/day) or the centrally acting 
sympatholytic clonidine (0.2 to 0.6 mg/day). The drug 
doses were titrated to reach a target diastolic blood 
pressure of less than 90 mm Hg. What were the main 
messages derived from this study? First, as antici- 
pated, all test drugs provided significantly greater 
blood pressure reductions than placebo. Second and 
most important, each of the therapeutic classes al- 
lowed the control of blood pressure in a substantial 
number of patients. This is shown in Figure 1. At the 
end of the titration phase, diastolic blood pressure was 
<90 mm Hg in more than half of the patients having 
received an active treatment. At 1 year, unfortunately, 
the results were less impressive, even if the criteria 
used to calculate the response rate were less severe 
(diastolic blood pressure ~90 mm Hg at the end of the 
titration phase and (95 mm Hg at the end of the 
study) than those used at the end of the titration 
phase. Thus, the antihypertensive efficacy of drugs 
given as monotherapy tended to wear off with time 
though a decreasing compliance over time could have 
been the cause of the seemingly reduced efficacy. Of 
note is that the dose increase was not associated in this 
trial with a decreased tolerability, at least as estimated 
by the withdrawal rate observed during administra- 
tion of low, medium, and high doses of the various 
agents. This is rather surprising considering the fact 
that a number of adverse drug reactions have a clear 
dose-dependent character.6 This is the case for diuret- 
ics (metabolic side effects), for P-blockers (mainly bra- 
dycardia, cardiac depression, and central side effects), 
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for ACE inhibitors (possibly cough), for calcium an- 
tagonists (vasodilatation-induced side effects, ie, 
edema, flushing, headaches, palpitations), for (pi- 
blockers (especially orthostatic hypotension), as well 
as for clonidine (central side effects, dry mouth). 
The study described above was carried out according 
to a parallel group design. It allows comparisons be- 
tween groups of patients, but does not tell anything 
about the differential blood pressure responses to the 
test compounds in a given patient. This is a key issue for 
the clinician who would like to know which type of 
antihypertensive agent he or she should prescribe pref- 
erentially in a given patient in order to get the highest 
probability of normalizing the patient’s blood pressure. 
Cross-over studies can provide the answer to this ques- 
tion, as each patient receives consecutively all treat- 
ments. Several crossover trials have been conducted to 
compare the efficacy of drugs acting by different mech- 
anisms, for example a P-blocker (betaxolol) and a cal- 
cium antagonist (verapamil),’ an ACE inhibitor (enala- 
pril) and a calcium antagonist (diltiazem),s a diuretic 
(hydrochlorothiazide), or an ACE inhibitor (lisinopril) 
and a calcium antagonist (nifedipine).’ In all these trials, 
the blood pressure responses were assessed by noninva- 
sive ambulatory blood pressure monitoring. A constant 
finding was that it is impossible to predict if a given 
patient will be a good responder or not. Some patients 
normalized their blood pressure whatever the drug 
used, some responded exclusively to one drug, whereas 
others remained hypertensive irrespective of the drug 
used. On this basis, one can conclude that sequential 
monotherapy is indeed a rational therapeutic approach 
as it offers the opportunity to identify the most suitable 
drug and to normalize blood pressure in many patients. 
One has to admit, however, that the search for an effec- 
tive and well tolerated antihypertensive agent may take 
a lot of time, as several 4 to 6 week treatment periods 
may be needed to find the most appropriate drug. 
THE RATIONALE FOR COMBINED THERAPY 
The combination of two drugs lowering blood pressure 
by different mechanisms is known to increase the frac- 
tion of hypertensive patients having their blood pressure 
controlled.‘,“’ The enhanced antihypertensive efficacy is 
probably related to the simultaneous attack on several 
regulatory systems involved in the abnormal blood pres- 
sure elevation. Also, all the vasoconstrictor systems are 
intimately interacting. It means that a blood pressure 
reduction resulting from the specific blockade of one 
system almost always triggers compensatory activation 
of other systems, with an ensuing attenuation of the 
overall antihypertensive efficacy. Another important 
point is that hopefully lower doses are needed when two 
drugs are co-administered than when they are given as 
single agents, although this is not always evident. Lower 
doses are important in terms of tolerability as the inci- 
dence of many side effects is dose dependent.h Theoret- 
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FIGURE 2. Blood pressure effect of various treatments admin- 
istered for 8 weeks after a 4 week run-in placebo period. L, 
lisinopril; HCTZ, hydrochlorothiazide (adapted from Chrysant 
SG13. 
ically, the most logical combinations consist of diuretics 
and ACE inhibitors, diuretics and P-blockers, calcium 
antagonists and P-blockers (particularly the dihy- 
dropyridines), and calcium antagonists and ACE 
inhibitorsi 
Diuretics and ACE Inhibitors The salt depletion in- 
duced by diuretics triggers the release of renin from 
juxtaglomerular cells. This reactive hyperreninemia 
renders blood pressure maintenance dependent on 
angiotensin II, blunting thereby the antihypertensive 
efficacy of diuretics. ii The addition of an ACE inhib- 
itor to a diuretic makes it possible to block the in- 
creased production of angiotensin II and, in this way, 
to enhance greatly the blood pressure lowering effect 
of salt depletion. Such a combination of drugs pro- 
vides advantages not only from the point of view of 
antihypertensive effectiveness, but also from that of 
tolerability. It is indeed well established that ACE 
inhibitors prevent or attenuate the metabolic side ef- 
fects of thiazide diuretics such as hypokalemia, hyper- 
glycemia, hypercholesterolemia, and hyperuricemia.” 
An example of a study involving an ACE inhibitor 
and a diuretic is given in Figure 2.13 In this trial, 
carried out in double-blind fashion, 505 patients 
whose diastolic blood pressure was 100 to 114 mm Hg 
were randomly assigned to an &week treatment with 
either the ACE inhibitor lisinopril, 10 mg/day, hydro- 
chlorothiazide, 12.5 or 25 mg/day, the combination of 
lisinopril, 10 mg/day and hydrochlorothiazide, 12.5 or 
25 mg/day, or placebo. It appeared that all active 
treatments significantly lowered blood pressure in 
comparison with placebo. The fall in blood pressure 
was of similar magnitude with the drugs used as 
monotherapy, but was more pronounced with the 
combined treatment. A key observation was that 12.5 
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and 25 mg hydrochlorothiazide were equally effective 
when administered together with lisinopril. In this 
study, cough was the only side effect encountered 
with an increased incidence in lisinopril-treated pa- 
tients. The 12.5 mg dose of hydrochlorothiazide, 
whether given alone or in association with lisinopril, 
was free of metabolic side effects, whereas the 25 mg 
dose caused a significant increase in serum glucose 
levels in both the presence and absence of simulta- 
neous ACE inhibition. The 25 mg dose of hydrochlo- 
rothiazide alone decreased significantly serum potas- 
sium levels, but this effect was not present anymore 
with concurrent lisinopril treatment. Based on these 
observations, a fixed-dose combination containing 10 
mg lisinopril and 12.5 mg hydrochlorothiazide is 
therefore appealing. 
Considering the use of a fixed-dose combination of 
an ACE inhibitor and a diuretic as first-choice antihy- 
pertensive treatment, one might be concerned by the 
potential risk of reducing blood pressure too much. 
Hypotensive episodes, however, do not represent a 
problem, as indicated by observations made in 263 
hypertensive patients aged 15 to 60 years and 276 
hypertensive patients older than 65, the latter being 
probably more prone than the former to develop or- 
thostatic hypotension.” All these patients exhibited a 
diastolic blood pressure in the range of 95 to 115 mm 
Hg when they entered the study and received once a 
day for 4 months a fixed-dose combination of 50 mg 
captopril plus 25 mg hydrochlorothiazide. Only one 
elderly patient had to interrupt the treatment because 
of hypotension. Of note is that a high rate of blood 
pressure normalization (defined as a diastolic blood 
pressure below 90 mm Hg) was obtained after 4 
months, at 83%) and 86%, in the younger and older 
patients, respectively. 
Diuretics and P-Blockers The combination of a di- 
uretic and a P-blocker has proved to be very effective 
in primary prevention drug trials and now represents 
a cornerstone for the treatment of hypertension. 
P-Blockers tend to suppress renin secretion and 
thereby attenuate the hyperreninemia induced by di- 
uretics. 
A recently reported trial has provided convincing 
evidence that a low-dose combination of a diuretic 
and a P-blocker is indeed efficacious and well 
tolerated.‘” In this trial, a total of 512 hypertensive 
patients with a diastolic blood pressure ranging from 
95 to 115 mm Hg at the end of a 4 to 6 week wash-out 
period were allocated to a 12 week double-blind treat- 
ment with bisoprolol (0, 2.5, 10, or 40 mg/day) plus 
placebo, bisoprolol (0, 2.5, 10 or 40 mg/day) plus 
hydrochlorothiazide, 6.25 mg/day, or bisoprolol (0, 
2.5, 10, or 40 mg/day) plus hydrochlorothiazide, 25 
mg/day. Figure 3 shows the response rate in the dif- 
ferent groups of patients. Bisoprolol given alone had a 
Dose of 
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* Sitting DBP 5 90 mmHg at week 12 
FIGURE 3. Response rate after a 12 zueek treatment with var- 
ious doses of bisoprolol and kydrocklorotkiazide (HCTZ) given in 
combination (adapted from Friskman WH et a115). 
dose-dependent blood pressure lowering effect. This 
was also true for the diuretic, the blood pressure con- 
trol being better with the 25 mg than with the 6.25 mg 
dose of hydrochlorothiazide. The major finding how- 
ever was that the association of 6.25 mg hydrochlo- 
rothiazide with the P-blocker gave results very similar 
to that of 25 mg hydrochlorothiazide with the 
P-blocker. Of note also is that there was no clear-cut 
advantage to increase the dose of bisoprolol from 2.5 
to 40 mg when the P-blocker was administered to- 
gether with the diuretic. Another issue to take into 
account is the tolerability. For instance, the 25 mg dose 
of hydrochlorothiazide significantly lowered serum 
potassium levels, which was not the case with the 6.25 
mg dose. It was concluded from this study that a fixed 
low-dose combination of bisoprolol and hydrochlo- 
rothiazide may be used in place of monotherapy as 
first-line treatment. This view was even supported by 
the US Food and Drug Administration, which ap- 
proved that fixed low-dose combination for the initi- 
ation of antihypertensive therapy.” It is worth quot- 
ing here the justification that led to the approval: “The 
pivotal consideration is that each of these agents (biso- 
pro101 and hydrochlorothiazide) has both dose-depen- 
dent and dose-independent adverse drug reactions. In 
a given patient, the dose-independent risks of the 
combination of low-dose bisoprolol and low-dose hy- 
drochlorothiazide might, therefore, be preferable to 
the dose-dependent risks associated with monotherapy 
that employed a higher dose of either agent.“i6 
The usefulness of a fixed-dose combination of biso- 
pro101 and hydrochlorothiazide for the initial treat- 
ment of hypertension has been directly compared 
with that of traditional monotherapies in a random- 
ized, double-blind, parallel group study.17 After a 4- to 
5-week placebo period, 218 hypertensive patients with 
diastolic blood pressures between 95 and 114 mm Hg 
were randomly allocated to take for 12 weeks either 
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the calcium antagonist amlodipine (2.5 to 10 mg/day), 
enalapril (5 to 20 mg/day), or the combination of 
bisoprolol(2.5 to 10 mg) with 6.25 mg hydrochlorothi- 
azide. The response rates (either a diastolic pressure 
~90 mm Hg or a decrease of diastolic pressure 210 
mm Hg) were 71% for the P-blocker-diuretic combi- 
nation, 69% for amlodipine, and 45% for enalapril. The 
overall incidence of adverse experiences was 29%, 
42%, and 47% for the drug combination, amlodipine, 
and enalapril, respectively. The corresponding values 
for the drug-related adverse events were 16%, 21%, 
and 23%. Thus the low-dose combination of bisoprolol 
and hydrochlorothiazide can indeed be regarded as a 
first-line option to replace single-agent therapies. 
&Blockers and Calcium Antagonists P-Blockers 
and dihydropyridine calcium antagonists complement 
each other when administered in combination. This is 
true not only in terms of antihypertensive efficacy, but 
also from the point of view of tolerability. Thus, 
P-blockers prevent the baroreceptor-reflex-mediated 
increase in heart rate observed in some patients dur- 
ing calcium entry blockade. On the other hand, the 
dihydropyridine-induced vasodilatation may attenu- 
ate the unwanted effects of P-blockade on the periph- 
eral circulation. P-blockers should not be associated 
with a phenylalkylamine such as verapamil, as there 
exists the risk of precipitating an atrioventricular 
block or a myocardial depression. For the same rea- 
son, caution must also be exerted when considering 
the association of a p-blocker with a benzothiazepine 
such as diltiazem. 
The usefulness of a P-blocker-calcium antagonist 
combination can be exemplified by the results of a 
double-blind, randomized, parallel group study 
aimed to compare extended-release formulations of 
either felodipine (10 mg/day) plus metoprolol (100 
mg/day), metoprolol (100 mg/day), or felodipine (10 
mg/day). ” The drugs were administered once daily 
for 12 weeks in a total of 159 hypertensive patients 
with a diastolic blood pressure >95 mm Hg. The 
reductions in blood pressure achieved during the 
course of the study were 20/14 mm Hg with the drug 
combination, 13/10 mm Hg with the calcium antago- 
nist, and 11/8 mm Hg with the P-blocker. The blood 
pressure control, as defined by a diastolic blood pres- 
sure <90 mm Hg after 12 weeks, was significantly 
better with the combination (71%) than with felodip- 
ine (49%) or metoprolol (34%). The three treatments 
were equally well tolerated. 
Further relevant findings have been reported from a 
double-blind, randomized, crossover trial in which 58 
hypertensive patients were treated for consecutive 12 
week periods with 5 to 10 mg/day of felodipine, 50 to 
100 mg/day of metoprolol, and a once-a-day fixed-dose 
combination of 5 to 10 mg felodipine plus 50 to 100 mg 
metoprolol.‘” Responders were defined by a diastolic 
Felodipine 
5.10mg 
n=26 
Metoprolol 
SO-100 mg 
n=23 
w 
Felodipine-Metoprolol 
5150 mg - lo/100 mg 
n=41 
FIGURE 4. Number of patients kaving normalized their dia- 
stolic blood pressure (590 mm Hg) after a 12 week treafment with 
felodipine and metoprolol given alove or in combination. The 
overlap between circles shows the patients who were good respond- 
ers to two or more of the treatments (adapted from Dakliif B 
et al’“). 
blood pressure 590 mm Hg and/or a decrease in dia- 
stolic blood pressure of 210 mm Hg at the end of the 
study. Figure 4 depicts the number of responders ob- 
served with the various treatments. It also shows the 
large heterogeneity in blood pressure responses, some 
patients being responders whatever the treatment used 
whereas some were responders during administration of 
two or even one drug only. The increased efficacy of the 
felodipine-metoprolol combination was obtained with- 
out compromising the tolerability, as compared with the 
component monotherapies. 
Calcium Antagonists and ACE Inhibitors Calcium 
antagonists and ACE inhibitors exhibit additive anti- 
hypertensive efficacy when combined, and their safety 
profile is, if anything, improved. For example, capto- 
pril co-administered with nifedipine decreases the in- 
cidence of ankle edema resulting from calcium entry 
blockade.‘” More importantly, ACE inhibition blunts 
the reflex increase in sympathetic nerve activity me- 
diated by dihydropyridines. This is illustrated in Fig- 
ure 5. In this study, 24 hypertensive patients with a 
diastolic blood pressure of 95 to 115 mm Hg at the end 
of a 3 to 4 week wash-out period were randomized to 
receive in single-blind fashion for 4 weeks either cap- 
topril, 50 mg twice a day, or nitrendipine, 20 mg once 
a day. For the following 4 weeks half of the patients 
were treated with placebo and half with nitrendipine, 
10 mg once a day, plus captopril, 25 mg twice a day.‘l 
In the panel A of Figure 5 are shown the patients 
treated initially with captopril. The ACE inhibitor pro- 
duced a significant fall in diastolic blood pressure with 
no concomitant change in heart rate. The patients 
randomized to placebo returned again to pretreatment 
blood pressure values whereas the association of cap- 
topril and nitrendipine led to an additional fall in 
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FIGURE 5. Blood pressure and heart rate response to captopril 
(Cl and nitrendipine (N,J administered alone or in combination. 
Panel A: patients initially treated with captopril. Panel 8: pa- 
tients initially treated with nitrendipi~re. (Adapted from Gennari 
C et al”). 
blood pressure, which was significant when compared 
with the ACE inhibitor alone, whereas heart rate re- 
mained stable. The panel B of Figure 5 depicts the 
patients treated with nitrendipine first. This calcium 
antagonist caused a significant blood pressure de- 
crease that was associated with a significant heart rate 
acceleration. Baseline values were reached again by 
those patients allocated to placebo during the last 4 
weeks of the study. In the remaining patients treated 
by the combination of nitrendipine, 10 mg/day, and 
captopril, 50 mg/day, a further significant fall in 
blood pressure was observed in comparison with the 
nitrendipine monotherapy phase. During combined 
treatment, however, there was no evidence anymore 
for a reflex increase in heart rate. Other studies have 
confirmed the effectiveness of combined treatment 
with an ACE inhibitor and a calcium antagonist. For 
example, isradipine (1.25 to 2.5 mg twice daily) as 
monotherapy, was found to normalize blood pressure 
after 6 months in 49% of hypertensive patients com- 
pared with 56%, with captopril as monotherapy (12.5 
to 25 mg twice daily).” Combining both drugs re- 
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sulted in an increased rate of blood pressure control, 
but not at the expense of a reduced tolerability. A 
potentially important advantage of this type of com- 
bination is that both calcium antagonists and ACE 
inhibitors are devoid of untoward metabolic effects. 
Other Potentially Useful Drug Combinations 
P-Blockers may well be combined with a,-blockers.” 
Labetalol is a racemic compound offering simulta- 
neously both types of adrenoceptor blockade. P-Block- 
ers might also be associated with ACE inhibitors re- 
sulting in a better control blood pressure in a number 
of patients.23 Diuretics may also increase the antihy- 
pertensive efficacy of calcium antagonists,2”,2” al- 
though such evidence has not been found.26 Actually, 
it has been suggested that the coadministration of a 
diuretic and a calcium antagonist may be as effective 
in lowering blood pressure as the combination of a 
diuretic with an ACE inhibitor.” A rational and 
widely accepted combination is that of a thiazide with 
a potassium-sparing diuretic. In the future, one might 
also consider to associate an ACE inhibitor with an 
angiotensin II receptor antagonist with the goal of 
rendering more complete the blockade of the renin- 
angiotensin system. 
THE NEED FOR FIXED-DOSE COMBINATIONS 
Already several years ago it has been recognized that 
fixed-dose combinations might be useful for the treat- 
ment of hypertension.*s At that time, most of the 
experience was based on the association of a diuretic 
with a centrally acting drug, mainly reserpine or 
methyldopa. Later on it was felt, however, that the use 
of fixed-ratio drug combinations should not be gener- 
alized, principally because of the lack of flexibility in 
adjusting the doses of the individual components. 
Fixed-dose combinations elicit nowadays a growing 
interest.2Y-“2 One realizes more and more that it is 
very difficult to find the most appropriate dose of two 
antihypertensive agents if one wishes to combine 
them in an attempt to normalize blood pressure of a 
given hypertensive patient. Frequently the dose titra- 
tion ends with the choice of too high doses, with the 
risk of favoring the occurrence of dose-related adverse 
reactions. The use of fixed-dose combinations greatly 
facilitates the therapeutic approach. The doctor knows 
that the doses of the two components were established 
on the basis of large clinical trials and that the primary 
aim was to develop a simple drug regimen that is at 
the same time efficacious and well tolerated. Fixed- 
dose combinations of antihypertensive agents are ex- 
pected to increase the patient’s compliance to therapy, 
as they enable to control blood pressure in many 
patients with a once-a-day administration. It is there- 
fore not really surprising that a highly respected reg- 
ulatory authority like the US Food and Drug Admin- 
istration has already approved a fixed-dose combina- 
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tion as a first-line antihypertensive therapy. No doubt 16. 
this will encourage many physicians to adopt this 
meaningful therapeutic approach. I” 
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